PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat

[1]  M. Karin,et al.  An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis , 2020, Science.

[2]  A. Duseja,et al.  Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. , 2019, Journal of clinical and experimental hepatology.

[3]  D. Schuppan,et al.  Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[4]  S. Sabbioni,et al.  Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma , 2019, Oncogene.

[5]  W. Seeger,et al.  Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis , 2019, Nature Communications.

[6]  D. Détaille,et al.  Role of Mitochondria in the Mechanism(s) of Action of Metformin , 2019, Front. Endocrinol..

[7]  Vahid Mohammadkarimi,et al.  Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial , 2019, European journal of gastroenterology & hepatology.

[8]  M. Larocca,et al.  Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration , 2019, Scientific Reports.

[9]  J. Gromada,et al.  Preemptive Activation of the Integrated Stress Response Protects Mice From Diet‐Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction , 2018, Hepatology.

[10]  B. Aronow,et al.  Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. , 2018, JCI insight.

[11]  M. Yoneda,et al.  Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.

[12]  Hai Yuan,et al.  Effect of AMPK signal pathway on pathogenesis of abdominal aortic aneurysms , 2017, Oncotarget.

[13]  G. Steinberg,et al.  AMPK as a Therapeutic Target for Treating Metabolic Diseases , 2017, Trends in Endocrinology & Metabolism.

[14]  R. Pais,et al.  Fatty liver and renal function impairment - Time for awareness? , 2017, Journal of hepatology.

[15]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[16]  W. Wahli,et al.  Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.

[17]  M. Bhat,et al.  AMPK, a key regulator of metabolic/energy homeostasis and mitochondrial biogenesis in cancer cells , 2016, Cell Death and Disease.

[18]  J. Boyer,et al.  Fibrates and cholestasis , 2015, Hepatology.

[19]  E. van Marck,et al.  PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. , 2015, Journal of hepatology.

[20]  Vanessa Souza-Mello,et al.  Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. , 2015, World journal of hepatology.

[21]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[22]  E. Fontaine,et al.  Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model , 2014, Diabetes.

[23]  B. Viollet,et al.  Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.

[24]  K. Petersen,et al.  The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes , 2014, Nature.

[25]  A. Gastaldelli,et al.  HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH , 2014, PloS one.

[26]  Shih-Yi Lin,et al.  Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats. , 2014, Endocrinology.

[27]  D. Rutkowski,et al.  The Stress-Regulated Transcription Factor CHOP Promotes Hepatic Inflammatory Gene Expression, Fibrosis, and Oncogenesis , 2013, PLoS genetics.

[28]  E. Mercken,et al.  Metformin improves healthspan and lifespan in mice , 2013, Nature Communications.

[29]  K. Ichihara,et al.  Inhibition of the TNF-α-induced serine phosphorylation of IRS-1 at 636/639 by AICAR. , 2013, Journal of pharmacological sciences.

[30]  Hao Wang,et al.  Activation of PPARα Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose–Fed Mice Despite Increased Endoplasmic Reticulum Stress , 2013, Diabetes.

[31]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[32]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[33]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[34]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[35]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[36]  C. C. Brackett.  Clarifying metformin's role and risks in liver dysfunction. , 2010, Journal of the American Pharmacists Association : JAPhA.

[37]  J. Suttles,et al.  Adenosine 5′-Monophosphate-Activated Protein Kinase Promotes Macrophage Polarization to an Anti-Inflammatory Functional Phenotype1 , 2008, The Journal of Immunology.

[38]  M. Katze,et al.  UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. , 2008, Developmental cell.

[39]  H. Tilg,et al.  Inflammatory Mechanisms in the Regulation of Insulin Resistance , 2008, Molecular medicine.

[40]  B. Göke,et al.  The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes , 2007, Diabetes & vascular disease research.

[41]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[42]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[43]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[44]  G. Targher,et al.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.

[45]  G. Gibbons,et al.  A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. , 2005, The Biochemical journal.

[46]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[47]  E. Bruckert,et al.  Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women , 2004, International Journal of Obesity.

[48]  Kohjiro Ueki,et al.  Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. , 2004, The Journal of clinical investigation.

[50]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[51]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[52]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.